WEBINAR: Beyond Syngeneics – Novel Tools for Addressing Human Specificity in Immuno-Oncology

Tuesday, October 31, 10:00 am EDT

Presented by Dr. John MacDougall this webinar presents novel humanized drug target models (e.g. for PD-1, CTLA-4, PD-L1) for investigating human specificity in immunocompetent mice, and evauating human-specific immuno-oncology agents in vivo.

NEW WHITE PAPER: The Ultimate Guide to Mouse Clinical Trials

Transform your preclinical oncology drug development, with mouse clinical trials using patient-derived xenograft (PDX) models. Learn how the different types of MCT are executed, which is the best fit for your specific drug discovery program, and how they provide the perfect framework for biomarker discovery.

Didn't Make it to AACR Tumor Immunology and Immunotherapy 2017?

Read and download our posters now!

Download posters on the microbiota influence on anti-PD-1 antitumor activity, how CD47 expression levels predict macrophage-mediated phagocytosis in immunotherapy, and validation of PBMC-reconstituted humanized models for immuno-oncology research.

Join us at Booth #601 at the AACR-NCI-EORTC International Conference

October 28-29, Philadelphia, PA

Don't miss our short-talk 'Transcriptomic analysis of patient-derived xenografts reveals heterogeneity in human and mouse stroma/immune compartments' and 13 scientific posters

Join us at the AACR New Horizons in Cancer Research Conference

November 6-9, Shanghai, China

Don't miss our 4 posters covering a range of immuno-oncology topics including combination checkpoint inhibitor and targeted agent treatment of syngeneic cell lines and flow-based phenotyping of tumor-infiltrating immune cells in novel immuno-oncology in vivo models.

ON DEMAND WEBINAR: The Ultimate Guide to Mouse Clinical Trials

Presented by Dr. John MacDougall this webinar presents Mouse Clinical Trials (MCT) using PDX models, and will help to guide you through the process of determining which MCT best suits the specific needs of any given drug development program.

NEW WHITE PAPER: A Guide to Selecting Your Next Immuno-Oncology Model

Improve your model selection decision for any immuno-oncology study by exploring the immunocompetent model types within this white paper. Learn more about the features, limitations and major uses of each type and how to apply them to your next study.

High Fidelity CRISPR Cell Line Engineering Services

Make better go/no-go decisions with CRISPR Engineered Cell Line Services.

CrownBio provides efficient, cost-effective gene editing services using licensed CRISPR/Cas9 technology. Our experts can generate knock in and knockout cell lines with vector controls that are tailored to meet your specific needs and help you advance your preclinical drug development programs.

Missed the Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference?

Poster: Humanized CD137 Models for Preclinical Drug Development

Preclinical Efficacy Evaluation of Agonistic CD137 Therapeutic Antibodies in Human CD137 Knock-In Mouse Models (HuGEMM™)

ON DEMAND WEBINAR: How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology

Presented by Dr. Keefe Chng and Dr Judith Gorski this webinar will help guide you through a study design process that will enable the greatest opportunity to generate robust, high-quality data, that gives maximum confidence to select new drug candidates and regulatory submissions.

Didn't Make it to Tumor Models Boston 2017?

Poster: Evaluate Human Specific CD137 Antibodies

Preclinical Efficacy Evaluation of Agonistic CD137 Therapeutic Antibodies in Human CD137 Knock-In Mouse Models (HuGEMM™)

ON DEMAND WEBINAR: Vascular and Neural Complications in Rodent Models of Obesity and Type 2 Diabetes

Watch this scientific webinar presented by Dr. Mark Yorek, Professor of Medicine at University of Iowa and Associate Chief of Staff for Research at Iowa City VA. He will discuss the challenges in modeling diabetic neuropathy and how the use of improved translational rodent models can impact Diabetes and Obesity pre-clinical studies.

Didn't Make it to ADA 2017?

Watch our poster presentations and download our posters now!

1820-P: The Depletion of Peripheral NK Cells and NK T Lymphocytes in a Spontaneously Diabetic Non-Human Primate Model

1881-P: Rhythmic Differences of Blood Glucose Circadian between Normoglycemic and Diabetic Non-Human Primates

ON-DEMAND WEBINAR: Are You Choosing the Right Model?

A Guide to Selecting Your Next Immuno-Oncology Model

Join our webinar to discover the wide range of in vivo immuno-oncology preclinical models available, and what to consider when choosing the correct model for your studies. Learn how current models are being used to progress combination regimens, including dual immunotherapies, and I/O agents plus other treatment modalities.

NEW WHITE PAPER: Translational Platforms to Model Pre-Diabetes, Diabetes, and Diabetic Complications

This White Paper explores a unique platform of highly translational models recapitulating multiple aspects of disease progression as seen in humans, for preclinical efficacy studies.

ON-DEMAND WEBINAR: Translational Platforms to Model Pre-Diabetes, Diabetes, and Complications

Join our webinar to discover the development and utility of CrownBio's unique continuum of translational platforms modeling diabetes and metabolic syndrome pathophysiology, progression, and complications. Learn how these platforms are predicting the efficacy and safety of anti-diabetic therapies in humans.

Didn't Make it to AACR 2017?

Read and download all of our 14 posters now!

Clarity with
Crown

Recognize your next clinical candidate when you see it.

Our Translational Platforms enable our clients to identify the right patients for the right treatment. Having models which more accurately mimic human disease and population dynamics are key to successfully translating promising compounds into successful clinical candidates, whether treating Oncology or Diabetes related diseases.

Magnify your
insights

Understand the mechanisms of disease.

Our scientific acumen and experience will give you a deeper understanding of not just the pharmacological profile of your compound, but more importantly, a clear understanding of which compounds to progress into the clinic. Take a look at our publications to get a deeper understanding of the depth of our scientific expertise.

Begin with the
end insight

Connecting science to patients.

We help our clients solve some of today's most pressing problems in oncology, cardiovascular, and metabolic disease by answering some of the most challenging questions about human biology.

Proud to Support Breast Cancer Awareness Month Donate

CVMD

Models of Obesity

obesity-img.jpg

CrownBio’s preclinical Translational Technology Platforms provide spontaneous & diet-induced obesity (DIO) models, to support the transition of new agents into the clinic.

Learn More

Oncology

Oncology Databases

databases-img.jpg

Our unique databases provide a curated source of well-characterized models available to use for drug discovery including PDX models, cell lines, and syngeneic models.

Learn More

CVMD

Diabetes Models

oncoexpress-img.jpg

Models of both Type 1 and Type 2 diabetes, including conventional, as well as unique, highly translatable models for in vivo efficacy studies of antidiabetic agents.

Learn More

Latest from our Blog

October 19, 2017

Quick Guide: Top 3 AML Approval Trends for 2017

Acute myeloid leukemia has been the focus of much drug development, but few drug approvals, for the past few decades. While there have been significant research efforts into characterizing AML, and improving patient outcomes, the standard therapy for most subtypes of newly diagnosed AML has remained unchanged for the last 40 years.

Read More

October 19, 2017

Quick Guide: Top 3 AML Approval Trends for 2017

Acute myeloid leukemia has been the focus of much drug development, but few drug approvals, for...

Read More

October 17, 2017

The Role of Gut Microbiota and Implications for IBD

Over the past 10 years, scientists have discovered that changes in the composition of the gut...

Read More

October 12, 2017

Organ-on-a-Chip: The Future of Improved Drug Discovery?

I’m a firm believer in the use of animal models in medical research. This is so for many...

Read More

October 10, 2017

ADA 2017 Video Poster Review

Naturally Diabetic NHP Immune Cell Changes Correspond to Human Type 2 Diabetes

While changes in...

Read More

October 5, 2017

What's Next for Immune Checkpoint Inhibitors: TIM-3?

Unlike negative regulators, such as PD-1 and CTLA-4 (which have been proposed as therapeutic...

Read More

Upcoming Events


October 20 - 24, 2017

American Association for the Study of Liver Disease: The Liver Meeting® 2017

Washington D.C.

www.aasld.org/events-professional-development/liver-meeting


October 26 - 30, 2017

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications

Booth #601, Philadelphia, PA

www.aacr.org
Review our Short-Talk and Scientific Posters


November 6 - 9, 2017

4th AACR New Horizons in Cancer Research Conference: Research Propelling Cancer Prevention and Cures

Shanghai, China

www.nhicr.aacr.asia
Review our Scientific Posters


November 9 - 11, 2017

First EASL Nonalcoholic Fatty Liver Disease (NAFLD) Summit:

Rome, Italy

Target-Oriented approach to Diagnosis and Pharmacotherapy of Nonalcoholic Steatohepatitis (NASH), a dialogue between Academia and Industry

www.events.easl.eu